Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ali Murat

Showing results (251-260 of 263) with videos related to

Pageof 27
Sort By:
Joint Diseases and Related Surgery|July 18, 2023
Systematic triage and treatment of earthquake victims: Our experience in a tertiary hospital after the 2023 Kahramanmaras earthquakeGüzelali Özdemir, Taner Karlıdağ, Olgun Bingöl, et al.
Journal of Cancer Research and Clinical Oncology|July 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group StudyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
Clinical Lung Cancer|August 14, 2025
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology GroupTuğba Akın Telli, Ali Murat Tatlı, Özkan Alan, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 2022
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology GroupMustafa Gürbüz, Yasin Kutlu, Erman Akkuş, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyPınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Scientific Reports|March 9, 2024
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSeda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, et al.
Pageof 27

Showing results (251-260 of 263) with videos related to

Sort By:
Pageof 27
Joint Diseases and Related Surgery|July 18, 2023
Systematic triage and treatment of earthquake victims: Our experience in a tertiary hospital after the 2023 Kahramanmaras earthquakeGüzelali Özdemir, Taner Karlıdağ, Olgun Bingöl, et al.
Journal of Cancer Research and Clinical Oncology|July 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group StudyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|January 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) studyBurak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel, et al.
Clinical Lung Cancer|August 14, 2025
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology GroupTuğba Akın Telli, Ali Murat Tatlı, Özkan Alan, et al.
Journal of Cancer Research and Clinical Oncology|September 1, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)Mutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Journal of Cancer Research and Clinical Oncology|June 10, 2022
Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology GroupMustafa Gürbüz, Yasin Kutlu, Erman Akkuş, et al.
Journal of Cancer Research and Clinical Oncology|April 6, 2022
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) studyPınar Gursoy, Ali Murat Tatli, Dilek Erdem, et al.
Medicine|May 24, 2024
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacySaadettin Kilickap, Akin Ozturk, Nuri Karadurmus, et al.
Future Oncology (London, England)|June 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group studyMutlu Hizal, Burak Bilgin, Nail Paksoy, et al.
Scientific Reports|March 9, 2024
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastasesSeda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, et al.
Pageof 27